Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP12 | P39900 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20445673 | 1.00 | CYP19A1 (0.46) | CYP19A1EPHX1GPR35CYP2C19CA12 | |
| SCHEMBL4425518 | 0.83 | EPHX1 (0.45) | CYP19A1EPHX1GPR35CYP2C19CA12 | |
| SCHEMBL14606265 | 0.83 | CYP19A1 (0.49) | CYP19A1EPHX1CYP2C19CA12CA1 | |
| SCHEMBL27976432 | 0.80 | CYP19A1 (0.42) | CYP19A1EPHX1GPR35CYP2C19CA12 | |
| SCHEMBL20455701 | 0.80 | KAT2B (0.36) | CYP19A1 | |
| SCHEMBL23018464 | 0.79 | CYP19A1 (0.54) | CYP19A1EPHX1CYP2C19NAAASMN1; SMN2 | |
| Hydrazine SCHEMBL3862636 | 0.79 | CYP19A1 (0.42) | CYP19A1EPHX1GPR35CYP2C19CA12 | |
| SCHEMBL686208 | 0.79 | CYP19A1 (0.50) | CYP19A1EPHX1GPR35CYP2C19CA12 | |
| SCHEMBL21454934 | 0.79 | CYP19A1 (0.54) | CYP19A1EPHX1CYP2C19NAAASMN1; SMN2 | |
| SCHEMBL14422671 | 0.79 | CYP19A1 (0.42) | CYP19A1EPHX1GPR35CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110392684-A | Novel heterocyclic compounds and its purposes in prevention or treatment bacterium infection | 拜欧蒂姆公司 | 2019-10-29 | — | — | CN | disclosed |
| WO-2018141986-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018141991-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018141991-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018141986-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-08-09 | — | — | WO | disclosed |
| EP-3357924-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-3357924-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-08-08 | — | — | EP | disclosed |
| CN-101687740-B | Processes for production of 2-bromo-2,2-difluoroethanol and 2-(alkylcarbonyloxy)-1,1-difluoroethanesulfonic acid salt | CENTRAL GLASS CO LTD | 2014-07-02 | — | — | CN | disclosed |
| US-8222448-B2 | Processes for production of 2-bromo-2,2-difluoroethanol and 2-(alkylcarbonyloxy)-1, 1-difluoroethanesulfonic acid salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8110711-B2 | Processes for production of 2-bromo-2,2-difluoroethanol and 2-(alkylcarbonyloxy)-1,1-difluoroethanesulfonic acid salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20110319652-A1 | Processes for Production of 2-Bromo-2,2-Difluoroethanol and 2-(Alkylcarbonyloxy)-1, 1-Difluoroethanesulfonic Acid Salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110015431-A1 | Processes for Production of 2-Bromo-2,2-Difluoroethanol and 2-(Alkylcarbonyloxy)-1,1-Difluoroethanesulfonic Acid Salt | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-01-20 | — | — | US | disclosed |
| CN-101687740-A | Processes for production of 2-bromo-2,2-difluoroethanol and 2-(alkylcarbonyloxy)-1,1-difluoroethanesulfonic acid salt | CENTRAL GLASS CO LTD | 2010-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319652-A1 | Processes for Production of 2-Bromo-2,2-Difluoroethanol and 2-(Alkylcarbonyloxy)-1, 1-Difluoroethanesulfonic Acid Salt | HAO2, SULT2A1, CYP2F1 | CYP19A1 1056/4885EPHX1 659/4885GPR35 4669/4885 |
| US-20110015431-A1 | Processes for Production of 2-Bromo-2,2-Difluoroethanol and 2-(Alkylcarbonyloxy)-1,1-Difluoroethanesulfonic Acid Salt | HAO2, SULT2A1, CYP2F1 | CYP19A1 1056/4885EPHX1 659/4885GPR35 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.